| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281584 | Clinical Gastroenterology and Hepatology | 2015 | 32 Pages |
Abstract
Based on an analysis of data from a large clinical trial, the level of HDV RNA at week 24 of treatment with pegylated interferon, with or without adefovir for 48 weeks, can identify patients who will test negative for HDV RNA 24 weeks after the end of treatment. This information can be used to help physicians manage patients receiving therapy for chronic hepatitis D.
Keywords
Treatment outcome predictionROCHDVHBsAgPPVAUCCDHEOTadefovir dipivoxilHepatitis B surface antigenpositive predictive valuenegative predictive valueconfidence intervalNPV یا negative predictive valuearea under the curveodds ratioHBVhepatitis B virushepatitis delta virusreceiver operator characteristicvirologic responseend of treatment
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Onur Keskin, Heiner Wedemeyer, Ali Tüzün, Kalliopi Zachou, Xheni Deda, George N. Dalekos, Benjamin Heidrich, Selcen Pehlivan, Stefan Zeuzem, Kendal Yalçın, Selim Gürel, Fehmi Tabak, Ramazan Idilman, Hakan Bozkaya, Michael Manns, Cihan Yurdaydin,